JSPR

Initial Stage 1 data evaluating ven s obafusp alfa in IgAN expected by year-end 2026 Announces e xpansion cohort in patients with FSGS , with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104), a first-in-class bifunctional biologic that simultaneously and selectively targets both the alternative and terminal complement pathways.

REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten public offering on September 18, 2025 (the "Warrants"). The purchase price is $0.324 in cash per Warrant, without interest (the "Offer Purchase Price"). The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon the exercise of the Warrants, thereby reducing the potential dilutive impact of the Warrants, and providing shareholders and prospective investors greater certainty as to the Company's capital structure. Warrants tendered in the Offer will be retired and cancelled.

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D.

REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C.

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders

Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value.

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.